GlassScriptPhysician profile
Jeffrey A Gordon
NPI 1609857119
$3,878.12
in general payments reported to CMS, 2019-2025
46 companies · $658 in 2025
The $658 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $237 · 2021: $569 · 2022: $182 · 2023: $634 · 2024: $812 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $361.91 | 2019-2025 | |
| Celgene Corporation | $358.31 | 2019-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $339.96 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $338.62 | 2019-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $189.49 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $179.91 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $156.37 | 2019-2024 | Ultomiris |
| Amgen INC. | $130.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.07 | 2020-2025 | Enhertu |
| Daiichi Sankyo INC. | $110.56 | 2021-2025 | Vanflyta, Enhertu, Injectafer |
| Eisai INC. | $103.51 | 2023-2025 | |
| Seagen INC. | $99.94 | 2019-2023 | Padcev |
| Taiho Oncology, INC. | $94.32 | 2021-2025 | |
| Janssen Biotech, INC. | $91.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.72 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.